Novo Nordisk ® weight or obesity demonstrated in the OASIS 1 phase 3 trial bo 1.8 17.4 % of patients Categorical weight loss % at week 68 100 89.2 80 74.7 60 58.5 40 24.5 20 0 ≥5% 11.8 ≥10% 37.2 5.3 ≥15% 2.4 ≥20% Oral sema 50 mg Placebo
Download PDF file